These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38540260)

  • 1. Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects.
    Pereira M; Vale N
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
    Foca M; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Britto P; Carey VJ; King J; Acosta EP; Cressey TR;
    Pediatr Infect Dis J; 2016 Sep; 35(9):e271-4. PubMed ID: 27187753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day
    Di Cristo V; Adorni F; Maserati R; Annovazzi Lodi M; Bruno G; Maggi P; Volpe A; Vitiello P; Abeli C; Bonora S; Ferrara M; Cossu MV; Oreni ML; Colella E; Rusconi S
    HIV Res Clin Pract; 2020 Feb; 21(1):34-43. PubMed ID: 32129161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
    Parsons TL; Marzinke MA
    J Pharm Biomed Anal; 2016 Nov; 131():333-344. PubMed ID: 27632783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
    PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.
    Fayet A; Béguin A; Zanolari B; Cruchon S; Guignard N; Telenti A; Cavassini M; Günthard HF; Buclin T; Biollaz J; Rochat B; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(11-12):1057-69. PubMed ID: 19332396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial).
    Abe E; Assoumou L; de Truchis P; Amat K; Gibowski S; Gras G; Bellet J; Saillard J; Katlama C; Costagliola D; Girard PM; Landman R; Alvarez JC
    Br J Clin Pharmacol; 2021 Apr; 87(4):1930-1939. PubMed ID: 33010058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enteral administration of crushed rilpivirine in a patient with HIV: A case report.
    Ragonnet G; Laroche H; Néant N; Benkouiten S; Dos Santos MC; Faucher-Zaegel O; Solas C; Bregigeon-Ronot S
    Br J Clin Pharmacol; 2024 Mar; 90(3):895-899. PubMed ID: 38163749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial.
    Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Rivas-Jeremías I; Espinosa N; Trujillo-Rodríguez M; Fernandez-Magdaleno T; Viciana P; López-Cortés LF
    Clin Infect Dis; 2017 Aug; 65(4):551-556. PubMed ID: 28449051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.
    Hirano A; Takahashi M; Kinoshita E; Shibata M; Nomura T; Yokomaku Y; Hamaguchi M; Sugiura W
    Biol Pharm Bull; 2010; 33(8):1426-9. PubMed ID: 20686242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction.
    Belkhir L; De Laveleye M; Vandercam B; Zech F; Delongie KA; Capron A; Yombi J; Vincent A; Elens L; Haufroid V
    Clin Biochem; 2016 May; 49(7-8):580-6. PubMed ID: 26742721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
    Vingerhoets J; Calvez V; Flandre P; Marcelin AG; Ceccherini-Silberstein F; Perno CF; Mercedes Santoro M; Bateson R; Nelson M; Cozzi-Lepri A; Grarup J; Lundgren J; Incardona F; Kaiser R; Sonnerborg A; Clotet B; Paredes R; Günthard HF; Ledergerber B; Hoogstoel A; Nijs S; Tambuyzer L; Lavreys L; Opsomer M;
    HIV Med; 2015 May; 16(5):297-306. PubMed ID: 25585664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
    Patel DA; Snedecor SJ; Tang WY; Sudharshan L; Lim JW; Cuffe R; Pulgar S; Gilchrist KA; Camejo RR; Stephens J; Nichols G
    PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir-based dual therapy in HIV experienced patients.
    Sterrantino G; Zaccarelli M; Di Biagio A; Rosi A; Bruzzone B; Cicconi P; Carli T; Biondi ML; Antinori A; Bartolozzi D; Penco G
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19782. PubMed ID: 25397526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The maraviroc expanded access program - safety and efficacy data from an open-label study.
    Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
    HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.